| 今开：0.0 | 昨收：0.44 |
| 最高：0.0 | 最低：0.0 |
| 涨停价：0.0 | 跌停价：0.0 |
| 总市值：6050304.0 |
chuminhua2021-03-16 17:53
3月15日，新型抗生素研发公司MelintaTherapeutics宣布美国FDA已批准其Kimyrsa（oritavancin），用于治疗由指定革兰氏阳性微生物的敏感分离株（包括耐甲氧西林金黄色葡萄球菌，MRSA）引起的急性细菌性皮肤和皮肤结构感染（ABSSSI）成人患者。Kimyrsa是一种糖肽类抗生素，1小时单剂输注1200 mg就可提...查看全文
医药魔方2019-12-31 09:21
继今年上半年开发抗生素的上市公司Achaogen申请破产之后，另外一家专注开发新型抗生素的上市公司Melinta Therapeutics也在近日按照《美国破产法典》第11章程序申请破产。
Melinta是Cempra制药公司的继承实体。Cempra制药公司位于北卡罗来纳州教堂山市，于2005年11月18日成立，是一家开发抗细菌...查看全文
用户48783635432019-04-10 11:18
【4月9日医药股盘点】$Histogenics(HSGX)$$PhaseBio制药(PHAS)$ $Melinta Therapeutics(MLNT)$ 细胞疗法公司Histogenics同制药公司Ocugen合并，上涨56%；制药公司PhaseBio Pharmaceuticals上涨17.15%；抗生素开发公司Melinta Therapeutics上涨15.15%等。查看全文网页链接查看全文
$Melinta Therapeutics, Inc.(MLNT)$ SC 13D/A [Amend] - General statement of acquisition of beneficial ownership Filed: 2018-11-08 AccNo: 0001193125-18-322611 Size: 78 KB 网页链接
$Melinta Therapeutics, Inc.(MLNT)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2018-11-07 AccNo: 0001461993-18-000006 Size: 9 MB 网页链接
$Melinta Therapeutics, Inc.(MLNT)$ 8-K - Current report Filed: 2018-11-07 AccNo: 0001193125-18-320215 Size: 7 MBItem 1.01: Entry into a Material Definitive AgreementItem 2.02: Results of Operations and Financial ConditionItem 3.02: Unregistered Sales of Equity SecuritiesItem ...
$Melinta Therapeutics, Inc.(MLNT)$ 8-K - Current report Filed: 2018-11-05 AccNo: 0001193125-18-318527 Size: 15 KBItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers http:/...
$Melinta Therapeutics, Inc.(MLNT)$ 8-K - Current report Filed: 2018-11-05 AccNo: 0001193125-18-318527 Size: 15 KBItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers http:/...
$Melinta Therapeutics, Inc.(MLNT)$ SC 13G - Statement of acquisition of beneficial ownership by individuals Filed: 2018-11-02 AccNo: 0000935836-18-000598 Size: 58 KB 网页链接
$Melinta Therapeutics, Inc.(MLNT)$ SC 13G - Statement of acquisition of beneficial ownership by individuals Filed: 2018-11-02 AccNo: 0000935836-18-000598 Size: 58 KB 网页链接
$Melinta Therapeutics, Inc.(MLNT)$ 美东时间 2018-11-07 盘前 披露财报，预期EPS -1.05 网页链接
$Melinta Therapeutics, Inc.(MLNT)$ 8-K - Current report Filed: 2018-10-24 AccNo: 0001193125-18-306463 Size: 190 KBItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain OfficersItem 9...
$Melinta Therapeutics, Inc.(MLNT)$ 8-K - Current report Filed: 2018-10-05 AccNo: 0001193125-18-294808 Size: 69 KBItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain OfficersItem 9....